6
IRUS Total
Downloads
  Altmetric

Evidence of a causal and modifiable relationship between kidney function and circulating trimethylamine N-oxide

File Description SizeFormat 
s41467-023-39824-4.pdfPublished version8.54 MBAdobe PDFView/Open
Title: Evidence of a causal and modifiable relationship between kidney function and circulating trimethylamine N-oxide
Authors: Andrikopoulos, P
Aron-Wisnewsky, J
Chakaroun, R
Myridakis, A
Forslund, S
Nielsen, T
Adriouch, S
Holmes, B
Chilloux, J
Vieira-Silva, S
Falony, G
Salem, J-E
Andreelli, F
Belda, E
Kieswich, J
Chechi, K
Puig-Castellvi, F
Chevalier, M
Le Chatelier, E
Olanipekun, M
Hoyles, L
Alves, R
Helft, G
Isnard, R
Køber, L
Coelho, LP
Rouault, C
Gauguier, D
Gøtze, JP
Prifti, E
Froguel, P
The MetaCardis, C
Zucker, J-D
Bäckhed, F
Vestergaard, H
Hansen, T
Oppert, J-M
Blüher, M
Nielsen, J
Raes, J
Bork, P
Yaqoob, M
Stumvoll, M
Pedersen, O
Ehrlich, SD
Clément, K
Dumas, M-E
Item Type: Journal Article
Abstract: The host-microbiota co-metabolite trimethylamine N-oxide (TMAO) is linked to increased cardiovascular risk but how its circulating levels are regulated remains unclear. We applied “explainable” machine learning, univariate, multivariate and mediation analyses of fasting plasma TMAO concentration and a multitude of phenotypes in 1,741 adult Europeans of the MetaCardis study. Here we show that next to age, kidney function is the primary variable predicting circulating TMAO, with microbiota composition and diet playing minor, albeit significant, roles. Mediation analysis suggests a causal relationship between TMAO and kidney function that we corroborate in preclinical models where TMAO exposure increases kidney scarring. Consistent with our findings, patients receiving glucose-lowering drugs with reno-protective properties have significantly lower circulating TMAO when compared to propensity-score matched control individuals. Our analyses uncover a bidirectional relationship between kidney function and TMAO that can potentially be modified by reno-protective anti-diabetic drugs and suggest a clinically actionable intervention for decreasing TMAO-associated excess cardiovascular risk.
Issue Date: 20-Sep-2023
Date of Acceptance: 30-Jun-2023
URI: http://hdl.handle.net/10044/1/105511
DOI: 10.1038/s41467-023-39824-4
ISSN: 2041-1723
Publisher: Nature Portfolio
Start Page: 1
End Page: 18
Journal / Book Title: Nature Communications
Volume: 14
Copyright Statement: © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Publication Status: Published
Conference Place: United Kingdom
Article Number: 5843
Online Publication Date: 2023-09-20
Appears in Collections:Department of Metabolism, Digestion and Reproduction
National Heart and Lung Institute
Faculty of Medicine
School of Public Health



This item is licensed under a Creative Commons License Creative Commons